Speaker Profile
Ph.D., Vice President, Capsid Discovery, Voyager Tx
Biography
Mathieu Nonnenmacher is currently leading the Novel Capsid Discovery group at Voyager Therapeutics, a Massachusetts gene therapy company using AAV for treatment of severe neurological diseases including Huntingtons disease, Friedreichs Ataxia and amyotrophic lateral sclerosis. During his postdoctoral training at Mount Sinai School of Medicine, Mathieu identified a natural mechanism of capsid-genome correlation that had important implications for the development of AAV libraries for Directed Evolution. Mathieu Joined Voyager Therapeutics in 2014 to develop capsid engineering for brain delivery. Since then, he established the TRACER biopanning platform which led to the discovery of numerous neurotrophic capsid variants in mouse and non-human primates. The Voyager team has recently discovered the mechanism of action of certain capsids, leading to the developments of novel viral and non-viral shuttles capable of crossing the blood-brain barrier.
Session Abstract – PMWC 2025 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Morten Sogaard, Astellas Gene Therapies
- PMWC 2025 Award Ceremony
Pioneer Honoree: James M. Wilson, Gemma Biotherapeutics
Luminary Honoree: Carolyn Bertozzi, Stanford
- Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation
- Carolyn Bertozzi, Stanford
- Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare
- James M. Wilson, Gemma Biotherapeutics
- Barriers in Gene Therapy
Chair: Timothy Hunt, Alliance for Regenerative Medicine
- Tay Salimullah, 4BIO Capital
- James M. Wilson, Gemma Biotherapeutics
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC) - Next-Generation Delivery Systems for Gene Therapies (PANEL)
Chair: James M. Wilson, Gemma Biotherapeutics
- Mathieu Nonnenmacher, Voyager Therapeutics
- Kevin Friedman, Kelonia Therapeutics
- Kunwoo Lee, GenEdit
- Haig Aghajanian, Capstan Therapeutics
- Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment (PANEL)
Chair: Charles Gersbach, Duke
- Prashant Mali, UCSD
- Nadav Ahituv, UCSF
- Blythe Sather, Tune Therapeutics
- Fyodor D Urnov, Berkely University
- Navigating the Regulatory Landscape for Gene and Cell Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Rob Califf, FDA
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC)
- Ben Dewees, Kyverna Therapeutics
- Paul Kruszka, GeneDx
- AI-driven Improvements in Gene and Cell Therapy (PANEL)
Chair: John Androsavich, Ginkgo Bioworks
- Francois Vigneault, Shape Therapeutics
- Eeshit Dhaval Vaishnav, Sequome
- Sam Sinai, Dyno Therapeutics
- Kira Radinsky, mana.bio
